http://www.nortonrose.comDescription© Copyright Norton Rose LLP 2013. All rights reserved.SaturdaySunday0123456789101113141517181920212223http://www.nortonrose.com/common/images/logo_reverse.gifhttp://www.nortonrose.comOn May 1, 2013, the United States Trade Representative (“USTR”) released its annual IP report for 2013. Canada has been placed on the “Watch List" for 2013 due...Fri, 03 May 2013 00:00:00 GMThttp://www.nortonrose.com/knowledge/publications/79960/pharma-in-brief-canada-ustr-slams-canada-over-the-treatment-of-pharmaceutical-patentshttp://www.nortonrose.com/knowledge/publications/79960/pharma-in-brief-canada-ustr-slams-canada-over-the-treatment-of-pharmaceutical-patentstext/plainOn April 26, 2013, Health Canada published a notice to inform clinical trial sponsors that information about clinical trials will be published.Tue, 30 Apr 2013 00:00:00 GMThttp://www.nortonrose.com/knowledge/publications/79827/pharma-in-brief-canada-health-canada-authorizes-publication-of-clinical-trial-informationhttp://www.nortonrose.com/knowledge/publications/79827/pharma-in-brief-canada-health-canada-authorizes-publication-of-clinical-trial-informationtext/plainLeading international legal practice Norton Rose has today announced 33 partner promotions globally including, in South Africa, six promotions to director.Wed, 24 Apr 2013 00:00:00 GMThttp://www.nortonrose.com/news/79649/norton-rose-announces-33-global-promotions-ahead-of-us-combinationhttp://www.nortonrose.com/news/79649/norton-rose-announces-33-global-promotions-ahead-of-us-combinationtext/plainAstraZeneca Canada Inc. and AstraZeneca AB (“AstraZeneca”) brought an application pursuant to section 6 of the Patented Medicines (Notice of Compliance)...Thu, 28 Mar 2013 00:00:00 GMThttp://www.nortonrose.com/knowledge/publications/77666/pharma-in-brief-canada-patent-for-esomeprazole-tablets-found-not-to-be-obvioushttp://www.nortonrose.com/knowledge/publications/77666/pharma-in-brief-canada-patent-for-esomeprazole-tablets-found-not-to-be-obvioustext/plainNovartis Pharmaceuticals Canada Inc. (“Novartis”) brought an application pursuant to s. 6 of the Patented Medicines (Notice of Compliance) Regulations for an...Fri, 22 Mar 2013 00:00:00 GMThttp://www.nortonrose.com/knowledge/publications/77402/pharma-in-brief-canada-federal-court-issues-prohibition-order-in-respect-of-zoledronatehttp://www.nortonrose.com/knowledge/publications/77402/pharma-in-brief-canada-federal-court-issues-prohibition-order-in-respect-of-zoledronatetext/plainTax has rarely been away from the headlines over the last few months. The Chancellor has faced repeated calls to clamp down on perceived tax avoidance, while at the Thu, 21 Mar 2013 00:00:00 GMThttp://www.nortonrose.com/knowledge/publications/77205/uk-budget-2013http://www.nortonrose.com/knowledge/publications/77205/uk-budget-2013text/plainAstraZeneca Canada Inc. and AstraZeneca UK Limited (“AstraZeneca”) brought an application pursuant to section 6 of the Patented Medicines (Notice of Compliance)...Wed, 20 Mar 2013 00:00:00 GMThttp://www.nortonrose.com/knowledge/publications/77262/pharma-in-brief-canada-federal-court-dismisses-prohibition-application-for-quetiapine-tabletshttp://www.nortonrose.com/knowledge/publications/77262/pharma-in-brief-canada-federal-court-dismisses-prohibition-application-for-quetiapine-tabletstext/plainApotex Inc. (“Apotex”) brought an action for impeachment seeking a declaration that Lundbeck’s Canadian Patent No. 1,339,452 (the “’452 Patent”) is invalid.Mon, 18 Mar 2013 00:00:00 GMThttp://www.nortonrose.com/knowledge/publications/77167/pharma-in-brief-canada-federal-court-upholds-validity-of-patent-for-escitalopram-cipralexhttp://www.nortonrose.com/knowledge/publications/77167/pharma-in-brief-canada-federal-court-upholds-validity-of-patent-for-escitalopram-cipralextext/plainJustice Jagot of the Federal Court of Australia has found three patents protecting AstraZeneca’s CRESTOR (rosuvastatin) product...Sun, 10 Mar 2013 00:00:00 GMThttp://www.nortonrose.com/knowledge/publications/76233/federal-court-delivers-significant-judgment-allowing-launch-of-generic-crestor-rosuvastatinhttp://www.nortonrose.com/knowledge/publications/76233/federal-court-delivers-significant-judgment-allowing-launch-of-generic-crestor-rosuvastatintext/plainOn 6 February 2013, the High Court of Australia handed down its unanimous decision in respect of Google Inc’s appeal against the decision of the Full Court of the...Thu, 28 Feb 2013 00:00:00 GMThttp://www.nortonrose.com/knowledge/publications/75846/google-succeeds-in-high-court-appealhttp://www.nortonrose.com/knowledge/publications/75846/google-succeeds-in-high-court-appealtext/plainTeva Canada Limited (“Teva”) and Apotex Inc. (“Apotex”) wish to sell generic versions of GLEEVEC®, a highly effective drug for the treatment of chronic myeloid...Tue, 26 Feb 2013 00:00:00 GMThttp://www.nortonrose.com/knowledge/publications/75752/pharma-in-brief-canada-federal-court-upholds-validity-of-gleevec-patenthttp://www.nortonrose.com/knowledge/publications/75752/pharma-in-brief-canada-federal-court-upholds-validity-of-gleevec-patenttext/plainThis was an appeal from a decision of the Federal Court granting Celgene Inc.’s (“Celgene”) application for judicial review and quashing a decision of the...Thu, 21 Feb 2013 00:00:00 GMThttp://www.nortonrose.com/knowledge/publications/75600/pharma-in-brief-canada-federal-court-of-appeal-reverses-lower-court-decision-and-holds-that-thalomid-is-not-an-innovative-drughttp://www.nortonrose.com/knowledge/publications/75600/pharma-in-brief-canada-federal-court-of-appeal-reverses-lower-court-decision-and-holds-that-thalomid-is-not-an-innovative-drugtext/plainFarah Mukaddam has written an article on the copyright dispute between online news publishers and news aggregators.Wed, 20 Feb 2013 00:00:00 GMThttp://www.nortonrose.com/news/77143/e-commerce-law-policy-online-news-aggregation-services-the-disputehttp://www.nortonrose.com/news/77143/e-commerce-law-policy-online-news-aggregation-services-the-disputetext/plainAn Australian Court has, for the first time, had the opportunity to consider whether human genetic information (in the form of nucleic acids, ie DNA and RNA) can be Tue, 19 Feb 2013 00:00:00 GMThttp://www.nortonrose.com/knowledge/publications/75482/australian-court-approves-human-gene-patentshttp://www.nortonrose.com/knowledge/publications/75482/australian-court-approves-human-gene-patentstext/plainEli Lilly Canada Inc. (“Lilly”) brought an application under the Patented Medicines (Notice of Compliance) Regulations (the “NOC Regulations”) for an Order...Mon, 28 Jan 2013 00:00:00 GMThttp://www.nortonrose.com/knowledge/publications/74727/pharma-in-brief-canada-federal-court-confirms-that-where-noa-is-withdrawn-pmnoc-application-for-a-prohibition-order-is-moothttp://www.nortonrose.com/knowledge/publications/74727/pharma-in-brief-canada-federal-court-confirms-that-where-noa-is-withdrawn-pmnoc-application-for-a-prohibition-order-is-moottext/plainThis was an appeal from the decision of the Federal Court which had dismissed Takeda’s application for judicial review of the Minister’s refusal to list Takeda’s...Wed, 23 Jan 2013 00:00:00 GMThttp://www.nortonrose.com/knowledge/publications/74623/pharma-in-brief-canada-federal-court-of-appeal-confirms-that-an-enantiomer-of-a-previously-approved-medicinal-ingredient-is-not-an-innovative-drughttp://www.nortonrose.com/knowledge/publications/74623/pharma-in-brief-canada-federal-court-of-appeal-confirms-that-an-enantiomer-of-a-previously-approved-medicinal-ingredient-is-not-an-innovative-drugtext/plainThis is the first proceeding under the Patented Medicine (Notice of Compliance Regulations) (“NOC Regulations”) brought by Apotex Inc. Tue, 22 Jan 2013 00:00:00 GMThttp://www.nortonrose.com/knowledge/publications/74566/pharma-in-brief-canada-ontario-superior-court-affirms-that-section-8-damages-do-not-include-disgorgement-of-innovators-profitshttp://www.nortonrose.com/knowledge/publications/74566/pharma-in-brief-canada-ontario-superior-court-affirms-that-section-8-damages-do-not-include-disgorgement-of-innovators-profitstext/plainThe Quebec government recently announced, as part of its budget, the intended abolishment of the rule known as “BAP-15.”Fri, 11 Jan 2013 00:00:00 GMThttp://www.nortonrose.com/knowledge/publications/74229/pharma-in-brief-canada-changes-in-quebec-pharmaceutical-reimbursement-policyhttp://www.nortonrose.com/knowledge/publications/74229/pharma-in-brief-canada-changes-in-quebec-pharmaceutical-reimbursement-policytext/plainJeremy Tan comments on the PDPA broad objectives.Wed, 09 Jan 2013 00:00:00 GMThttp://www.nortonrose.com/news/74266/thomson-reuters-singapore-becomes-latest-country-in-asia-to-introduce-personal-data-privacy-lawhttp://www.nortonrose.com/news/74266/thomson-reuters-singapore-becomes-latest-country-in-asia-to-introduce-personal-data-privacy-lawtext/plainNorton Rose is advising Delta Air Lines, Inc. in relation to the proposed US$360 million acquisition of a 49 per cent stake in Virgin Atlantic from Singapore AirlineTue, 11 Dec 2012 00:00:00 GMThttp://www.nortonrose.com/news/73500/norton-rose-advises-on-delta-airlines-proposed-us360-million-stake-in-virgin-atlantichttp://www.nortonrose.com/news/73500/norton-rose-advises-on-delta-airlines-proposed-us360-million-stake-in-virgin-atlantictext/plainNorton Rose has fielded a team from London and Johannesburg to advise Barclays on the combination of the majority of its African operations with Absa Group.Thu, 06 Dec 2012 00:00:00 GMThttp://www.nortonrose.com/news/73290/norton-rose-advising-barclays-on-combination-of-barclays-african-operations-with-absa-grouphttp://www.nortonrose.com/news/73290/norton-rose-advising-barclays-on-combination-of-barclays-african-operations-with-absa-grouptext/plainIn the coming year the TGA will aim to change the way pharmaceuticals can be labelled to restrict some brand extensions. There will be new obligations to clear...Thu, 29 Nov 2012 00:00:00 GMThttp://www.nortonrose.com/knowledge/publications/73067/pharmaceutical-brand-owners-beware-changes-to-medicine-packaging-aheadhttp://www.nortonrose.com/knowledge/publications/73067/pharmaceutical-brand-owners-beware-changes-to-medicine-packaging-aheadtext/plainLegal Week reports that Huw Evans is to join the IP practice.Fri, 23 Nov 2012 00:00:00 GMThttp://www.nortonrose.com/news/72935/legal-week-norton-rose-takes-on-ao-ip-partnerhttp://www.nortonrose.com/news/72935/legal-week-norton-rose-takes-on-ao-ip-partnertext/plainThe legal battle between Apple Inc. and Samsung Electronics Co. can best be described as an epic battle.Thu, 22 Nov 2012 00:00:00 GMThttp://www.nortonrose.com/knowledge/publications/72984/strange-bedfellows-applesamsunghttp://www.nortonrose.com/knowledge/publications/72984/strange-bedfellows-applesamsungtext/plainSecuring registration of a trade mark does not guarantee an endless monopoly in the mark.Thu, 22 Nov 2012 00:00:00 GMThttp://www.nortonrose.com/knowledge/publications/72985/protecting-your-trade-markhttp://www.nortonrose.com/knowledge/publications/72985/protecting-your-trade-marktext/plain